Marker Therapeutics Inc. [NASDAQ: MRKR] plunged by -$0.2 during the normal trading session on Monday and reaching a high of $3.28 during the day while it closed the day at $3.01. The company report on June 17, 2021 that Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference.
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m. ET.
A live webcast of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.
Marker Therapeutics Inc. stock has also loss -15.45% of its value over the past 7 days. However, MRKR stock has inclined by 5.24% in the 3 months of the year. Over the past six months meanwhile, it has gained 89.31% and gained 107.59% year-on date.
The market cap for MRKR stock reached $260.79 million, with 83.01 million shares outstanding and 59.78 million shares in the current float. Compared to the average trading volume of 3.76M shares, MRKR reached a trading volume of 2116856 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Marker Therapeutics Inc. [MRKR]:
Piper Sandler have made an estimate for Marker Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 25, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on March 19, 2021, representing the official price target for Marker Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Piper Sandler kept a Neutral rating on MRKR stock.
The Average True Range (ATR) for Marker Therapeutics Inc. is set at 0.23, with the Price to Sales ratio for MRKR stock in the period of the last 12 months amounting to 521.57. The Price to Book ratio for the last quarter was 2.35, with the Price to Cash per share for the same quarter was set at 0.74.
MRKR stock trade performance evaluation
Marker Therapeutics Inc. [MRKR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.45. With this latest performance, MRKR shares gained by 19.44% in over the last four-week period, additionally plugging by 89.31% over the last 6 months – not to mention a rise of 46.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRKR stock in for the last two-week period is set at 50.84, with the RSI for the last a single of trading hit 44.75, and the three-weeks RSI is set at 53.45 for Marker Therapeutics Inc. [MRKR]. The present Moving Average for the last 50 days of trading for this stock 2.63, while it was recorded at 3.21 for the last single week of trading, and 2.07 for the last 200 days.
Marker Therapeutics Inc. [MRKR]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Marker Therapeutics Inc. [MRKR] shares currently have an operating margin of -6188.25. Marker Therapeutics Inc.’s Net Margin is presently recorded at -6149.74.
Return on Total Capital for MRKR is now -68.63, given the latest momentum, and Return on Invested Capital for the company is -68.69. Return on Equity for this stock declined to -80.37, with Return on Assets sitting at -62.42. When it comes to the capital structure of this company, Marker Therapeutics Inc. [MRKR] has a Total Debt to Total Equity ratio set at 44.83. Additionally, MRKR Total Debt to Total Capital is recorded at 30.95, with Total Debt to Total Assets ending up at 26.87. Long-Term Debt to Equity for the company is recorded at 43.40, with the Long-Term Debt to Total Capital now at 29.97.
Reflecting on the efficiency of the workforce at the company, Marker Therapeutics Inc. [MRKR] managed to generate an average of -$652,411 per employee. Receivables Turnover for the company is 0.88 with a Total Asset Turnover recorded at a value of 0.01.Marker Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.30 and a Current Ratio set at 16.30.
Earnings per share (EPS) analysis for Marker Therapeutics Inc. [MRKR] stock
With the latest financial reports released by the company, Marker Therapeutics Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRKR.
Marker Therapeutics Inc. [MRKR]: Insider Ownership positions
There are presently around $76 million, or 33.70% of MRKR stock, in the hands of institutional investors. The top three institutional holders of MRKR stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 10,714,285, which is approximately 114.286% of the company’s market cap and around 13.10% of the total institutional ownership; AISLING CAPITAL MANAGEMENT LP, holding 3,142,857 shares of the stock with an approximate value of $9.46 million in MRKR stocks shares; and VANGUARD GROUP INC, currently with $7.67 million in MRKR stock with ownership of nearly 83.128% of the company’s market capitalization.
Positions in Marker Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 42 institutional holders increased their position in Marker Therapeutics Inc. [NASDAQ:MRKR] by around 12,125,691 shares. Additionally, 23 investors decreased positions by around 811,360 shares, while 15 investors held positions by with 12,456,049 shares. The mentioned changes placed institutional holdings at 25,393,100 shares, according to the latest SEC report filing. MRKR stock had 21 new institutional investments in for a total of 3,513,578 shares, while 7 institutional investors sold positions of 604,293 shares during the same period.